TCMCB07 is a peptide antagonist of melanocortin receptor 1 (MC1R), MC3R, MC4R, and MC5R (IC50s = 19.5, 0.59, 13.58, and 8.07 nM, respectively, for the human receptors).1 It is also an antagonist of dog MC1R, MC3R, MC4R, and MC5R receptors (IC50s = 53.64, 1.46, 7.14, and 11.22 nM, respectively). TCMCB07 (10 mg/kg) increases food intake and body weight in a rat model of LPS-induced cachexia. It increases body weight, muscle mass, blood levels of urea nitrogen, and mean heart rate in dogs with cachexia when administered at a dose of 0.75 mg/kg per day.2
References:
[1]. Gruber, K.A., Ji, R.L., Gallazzi, F., et al.Development of a therapeutic peptide for cachexia suggests a platform approach for drug-like peptidesACS Pharmacol. Transl. Sci.5(5)344-361(2022).
[2]. Axiak-Bechtel, S.M., Leach, S.B., Newton-Northup, J.R., et al.Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexiaJ. Vet. Intern. Med.37(6)2344-2355(2023).